Hippocratic AI Expands Life Sciences Leadership Team as Pharma and Medtech Demand for Voice AI Agents Accelerates

Hippocratic AI, the global leader and pioneer of safe generative AI healthcare agents, announced new senior executive appointments expanding its life sciences leadership team as the company scales its pharma and medtech business. The appointments — across engineering, medical affairs, commercial growth, and compliance — follow Hippocratic AI's January 2026 acquisition of Grove AI and the launch of Polaris Life Sciences 5.0, and signal the company's emergence as the industry's category-defining voice and conversational AI platform for pharma, biotech, and medtech.

"Hippocratic AI is now the established voice and conversational AI platform for life sciences, and we are attracting the most senior leaders in the field," said Ahad Wahid, President, Life Sciences. "Sri, Toby, John, Himanshu, and Sulaiman together bring more than a century of operating experience across pharma, biotech, and medtech — exactly the bench required to deliver safe, compliant generative AI agents at the scale and standard our life sciences partners demand."